These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 11207349)

  • 21. Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling.
    Larsen MJ; Kruse TA; Tan Q; Lænkholm AV; Bak M; Lykkesfeldt AE; Sørensen KP; Hansen TV; Ejlertsen B; Gerdes AM; Thomassen M
    PLoS One; 2013; 8(5):e64268. PubMed ID: 23704984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors.
    Bane AL; Pinnaduwage D; Colby S; Reedijk M; Egan SE; Bull SB; O'Malley FP; Andrulis IL
    Breast Cancer Res Treat; 2009 Sep; 117(1):183-91. PubMed ID: 18563556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations.
    Honrado E; Osorio A; Palacios J; Benitez J
    Oncogene; 2006 Sep; 25(43):5837-45. PubMed ID: 16998498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes.
    Vehmanen P; Friedman LS; Eerola H; McClure M; Ward B; Sarantaus L; Kainu T; Syrjäkoski K; Pyrhönen S; Kallioniemi OP; Muhonen T; Luce M; Frank TS; Nevanlinna H
    Hum Mol Genet; 1997 Dec; 6(13):2309-15. PubMed ID: 9361038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations.
    Tirkkonen M; Johannsson O; Agnarsson BA; Olsson H; Ingvarsson S; Karhu R; Tanner M; Isola J; Barkardottir RB; Borg A; Kallioniemi OP
    Cancer Res; 1997 Apr; 57(7):1222-7. PubMed ID: 9102202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
    Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD
    Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families.
    Ikeda N; Miyoshi Y; Yoneda K; Shiba E; Sekihara Y; Kinoshita M; Noguchi S
    Int J Cancer; 2001 Jan; 91(1):83-8. PubMed ID: 11149425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.
    Håkansson S; Johannsson O; Johansson U; Sellberg G; Loman N; Gerdes AM; Holmberg E; Dahl N; Pandis N; Kristoffersson U; Olsson H; Borg A
    Am J Hum Genet; 1997 May; 60(5):1068-78. PubMed ID: 9150154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germ line BRCA1 and BRCA2 gene mutations in Turkish breast cancer patients.
    Ozdag H; Tez M; Sayek I; Müslümanoglu M; Tarcan O; Içli F; Oztürk M; Ozçelik T
    Eur J Cancer; 2000 Oct; 36(16):2076-82. PubMed ID: 11044644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRCA1 and BRCA2 gene mutation analysis: visit to the Breast Cancer Information Core (BIC).
    Shen D; Vadgama JV
    Oncol Res; 1999; 11(2):63-9. PubMed ID: 10489161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
    Gayther SA; de Foy KA; Harrington P; Pharoah P; Dunsmuir WD; Edwards SM; Gillett C; Ardern-Jones A; Dearnaley DP; Easton DF; Ford D; Shearer RJ; Kirby RS; Dowe AL; Kelly J; Stratton MR; Ponder BA; Barnes D; Eeles RA
    Cancer Res; 2000 Aug; 60(16):4513-8. PubMed ID: 10969800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers.
    Phillips KA
    J Clin Oncol; 2000 Nov; 18(21 Suppl):107S-12S. PubMed ID: 11060337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCA1 and BRCA2 in breast cancer.
    Yang X; Lippman ME
    Breast Cancer Res Treat; 1999 Mar; 54(1):1-10. PubMed ID: 10369075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of DNA-damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients.
    Walker LC; Thompson BA; Waddell N; ; Grimmond SM; Spurdle AB
    PLoS Genet; 2010 Feb; 6(2):e1000850. PubMed ID: 20174566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
    Vos S; Moelans CB; van Diest PJ
    Breast Cancer Res; 2017 May; 19(1):64. PubMed ID: 28569220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MYB oncogene amplification in hereditary BRCA1 breast cancer.
    Kauraniemi P; Hedenfalk I; Persson K; Duggan DJ; Tanner M; Johannsson O; Olsson H; Trent JM; Isola J; Borg A
    Cancer Res; 2000 Oct; 60(19):5323-8. PubMed ID: 11034064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.
    Lakhani SR; Jacquemier J; Sloane JP; Gusterson BA; Anderson TJ; van de Vijver MJ; Farid LM; Venter D; Antoniou A; Storfer-Isser A; Smyth E; Steel CM; Haites N; Scott RJ; Goldgar D; Neuhausen S; Daly PA; Ormiston W; McManus R; Scherneck S; Ponder BA; Ford D; Peto J; Stoppa-Lyonnet D; Bignon YJ; Struewing JP; Spurr NK; Bishop DT; Klijn JG; Devilee P; Cornelisse CJ; Lasset C; Lenoir G; Barkardottir RB; Egilsson V; Hamann U; Chang-Claude J; Sobol H; Weber B; Stratton MR; Easton DF
    J Natl Cancer Inst; 1998 Aug; 90(15):1138-45. PubMed ID: 9701363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
    Zweemer RP; Shaw PA; Verheijen RM; Ryan A; Berchuck A; Ponder BA; Risch H; McLaughlin JR; Narod SA; Menko FH; Kenemans P; Jacobs IJ
    J Clin Pathol; 1999 May; 52(5):372-5. PubMed ID: 10560359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer.
    Steinmann D; Bremer M; Rades D; Skawran B; Siebrands C; Karstens JH; Dörk T
    Br J Cancer; 2001 Sep; 85(6):850-8. PubMed ID: 11556836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple copies of mutant BRCA1 and BRCA2 alleles in breast tumors from germ-line mutation carriers.
    Staff S; Nupponen NN; Borg A; Isola JJ; Tanner MM
    Genes Chromosomes Cancer; 2000 Aug; 28(4):432-42. PubMed ID: 10862052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.